

Richard Haynes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2959438/publications.pdf>

Version: 2024-02-01

86

papers

19,018

citations

136950

32

h-index

62596

80

g-index

99

all docs

99

docs citations

99

times ranked

31763

citing authors

#	ARTICLE	IF	CITATIONS
1	Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 2022, 37, 1317-1329.	0.7	58
2	Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal, 2022, 43, 2010-2019.	2.2	18
3	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	27.0	8,063
4	TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 123-130.	2.0	9
5	Conventional and Genetic Evidence on the Association between Adiposity and CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 127-137.	6.1	39
6	Tocilizumab in COVID-19 therapy: who benefits, and how? "Authors' reply. Lancet, The, 2021, 398, 300.	13.7	3
7	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	7.1	36
8	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
9	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163.	7.1	33
10	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK. JAMA Network Open, 2021, 4, e2139748.	5.9	15
11	Chronic kidney disease, heart failure and neprilysin inhibition. Nephrology Dialysis Transplantation, 2020, 35, 558-564.	0.7	39
12	Kidney disease trials for the 21st century: innovations in design and conduct. Nature Reviews Nephrology, 2020, 16, 173-185.	9.6	14
13	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 47-60.	4.5	41
14	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	27.0	1,013
15	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	13.7	569
16	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	5.2	65
17	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. International Journal of Obesity, 2020, 44, 2256-2266.	3.4	9
18	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. European Heart Journal, 2020, 41, 3336-3342.	2.2	27

#	ARTICLE	IF	CITATIONS
19	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1330.	7.4	1,855
20	Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence. Nephrology Dialysis Transplantation, 2020, 35, 1465-1468.	0.7	0
21	Effects of Omega-3 Fatty Acid Supplements on Arrhythmias. Circulation, 2020, 141, 331-333.	1.6	15
22	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2â€“Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. Clinical Therapeutics, 2019, 41, 1767-1777.	2.5	12
23	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
24	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. JAMA Network Open, 2019, 2, e190223.	5.9	16
25	Investigating modifications to participant information materials to improve recruitment into a large randomized trial. Trials, 2019, 20, 681.	1.6	3
26	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.7	6
27	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. Kidney International, 2018, 93, 1165-1174.	5.2	21
28	The role of lipoprotein (a) in chronic kidney disease. Journal of Lipid Research, 2018, 59, 577-585.	4.2	77
29	ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American Heart Journal, 2018, 198, 135-144.	2.7	78
30	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) â€“ results of a randomized controlled clinical trial. American Journal of Transplantation, 2018, 18, 1424-1434.	4.7	18
31	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	5.2	32
32	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. CKJ: Clinical Kidney Journal, 2018, 11, 749-761.	2.9	196
33	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation Genomic and Precision Medicine, 2018, 11, e001696.	3.6	65
34	PCSK9 inhibition: ready for prime time in CKD?. Kidney International, 2018, 93, 1267-1269.	5.2	11
35	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2018, 29, 2015-2027.	6.1	140
36	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation, 2018, 138, 1505-1514.	1.6	145

#	ARTICLE	IF	CITATIONS
37	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine, 2018, 379, 1529-1539.	27.0	823
38	Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. New England Journal of Medicine, 2018, 379, 1540-1550.	27.0	510
39	Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal) Tj ETQq1 1 0.784314 rgBT /Ove	1.7	10
40	Biliary Tract and Liver Complications in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 2738-2748.	6.1	19
41	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	2.7	30
42	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 546-552.	4.5	41
43	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	2.9	21
44	Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events in Diabetes (ASCEND). Trials, 2016, 17, 286.	1.6	34
45	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1794-1801.	4.5	22
46	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology, 2016, 4, 829-839.	11.4	234
47	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 348-354.	2.2	8
48	Outcomes of Elderly Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Treated with Immunosuppressive Therapy. Nephron, 2016, 133, 223-231.	1.8	1
49	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	1.9	57
50	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 591-598.	1.9	74
51	Niacin: old habits die hard. Heart, 2016, 102, 170-171.	2.9	1
52	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	1.9	42
53	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
54	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	1.8	82

#	ARTICLE	IF	CITATIONS
55	Statins in chronic kidney disease: time to move on?. Nature Reviews Nephrology, 2015, 11, 262-263.	9.6	5
56	Neprilysin inhibition in chronic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 738-743.	0.7	80
57	Alemtuzumab induction therapy in kidney transplantation – Authors' reply. Lancet, The, 2015, 385, 771.	13.7	0
58	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	1.1	0
59	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	1.3	49
60	Niacin for Reduction of Cardiovascular Risk. New England Journal of Medicine, 2014, 371, 1940-1944.	27.0	7
61	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	6.1	142
62	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2014, 64, 40-48.	1.9	55
63	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet, The, 2014, 384, 1684-1690.	13.7	124
64	Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine, 2014, 371, 203-212.	27.0	1,367
65	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	4.5	19
66	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplantation Research, 2013, 2, 7.	1.5	21
67	Quiz Page September 2013. American Journal of Kidney Diseases, 2013, 62, A26-A29.	1.9	2
68	Does serum phosphate predict death and ESRD in CKD patients?. Nature Reviews Nephrology, 2013, 9, 438-439.	9.6	5
69	Homocysteine, the kidney, and vascular disease. BMJ, The, 2012, 344, e3925-e3925.	6.0	6
70	Survival after Starting Renal Replacement Treatment in Patients with Autosomal Dominant Polycystic Kidney Disease: A Single-Centre 40-Year Study. Nephron Clinical Practice, 2012, 120, c42-c47.	2.3	14
71	Myeloma Kidney: Improving Clinical Outcomes?. Advances in Chronic Kidney Disease, 2012, 19, 342-351.	1.4	11
72	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5

#	ARTICLE	IF	CITATIONS
73	Alemtuzumab: right drug, right dose?*. Transplant International, 2011, 24, 1051-1052.	1.6	3
74	Clinical trials of lipid-modifying agents: design considerations. Clinical Lipidology, 2011, 6, 109-116.	0.4	0
75	Serum Free Light Chains and the Risk of ESRD and Death in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2829-2837.	4.5	35
76	Late presentation of patients with end-stage renal disease for renal replacement therapy--is it always avoidable?. Nephrology Dialysis Transplantation, 2011, 26, 3646-3651.	0.7	27
77	Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B ₁₂ vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors. JAMA - Journal of the American Medical Association, 2010, 303, 2486.	7.4	283
78	How the NHS research governance procedures could be modified to greatly strengthen clinical research. Clinical Medicine, 2010, 10, 127-129.	1.9	7
79	Screening for risk with albuminuria: should we start from here?. Nephrology Dialysis Transplantation, 2010, 25, 3463-3465.	0.7	1
80	LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care, 2010, 36, 27-33.	1.2	14
81	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet, The, 2010, 376, 1658-1669.	13.7	501
82	Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes. Nature Reviews Nephrology, 2009, 5, 126-127.	9.6	1
83	Dual blockade of the renin-angiotensin system: are two better than one?. Nephrology Dialysis Transplantation, 2009, 24, 3602-3607.	0.7	8
84	Aspirin for primary prevention of vascular disease in people with diabetes. BMJ: British Medical Journal, 2009, 339, b4596-b4596.	2.3	4
85	Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. Nature Clinical Practice Nephrology, 2007, 3, 530-531.	2.0	0
86	Proteinuria. BMJ: British Medical Journal, 2006, 332, 284.	2.3	7